Keeping RAASi Therapy After High Potassium Levels Can Prevent Hospitalization
Author Information
Author(s): Maria K. Svensson, Michael Fischereder, Paul R. Kalra, Ignacio José Sánchez Lázaro, Eva Lesén, Stefan Franzén, Alaster Allum, Thomas Cars, Nils Kossack, Philipp Breitbart, David Arroyo
Primary Institution: Uppsala University, Uppsala, Sweden
Hypothesis
Can maintaining RAASi therapy after a hyperkalemia episode reduce hospitalization rates?
Conclusion
Maintaining RAASi therapy after a hyperkalemia episode may help avoid hospitalizations.
Supporting Evidence
- Reducing RAASi therapy after hyperkalemia increases hospitalization risk.
- 25 patients need to maintain RAASi therapy to avoid one hospitalization.
- Patients with CKD and/or HF were studied across four European countries.
- RAASi therapy is often reduced after hyperkalemia, leading to worse outcomes.
- Maintaining RAASi therapy aligns with clinical guidelines.
Takeaway
If patients keep taking their heart and kidney medicine after having high potassium levels, they might not have to go to the hospital as much.
Methodology
The study used health care registers and claims data from four European countries to compare hospitalization risks between patients who reduced versus maintained RAASi therapy after hyperkalemia.
Potential Biases
Some residual confounding may remain due to the observational nature of the study.
Limitations
The study may have underestimated hospitalization risk by excluding patients with less follow-up time, potentially leading to a healthier sample.
Participant Demographics
Patients were mostly elderly, with a mean age of 75.7 to 78.6 years, and included both men and women with CKD and/or HF.
Statistical Information
P-Value
4.1%
Confidence Interval
95% CI, 2.8 to 5.3
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website